See more : Toga Limited (TOGL) Income Statement Analysis – Financial Results
Complete financial analysis of WuXi XDC Cayman Inc (2268.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of WuXi XDC Cayman Inc, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Bank of America Corporation (BAC-PL) Income Statement Analysis – Financial Results
- Garware Hi-Tech Films Limited (GRWRHITECH.BO) Income Statement Analysis – Financial Results
- Chokwang Leather Co.,Ltd. (004700.KS) Income Statement Analysis – Financial Results
- PT Danasupra Erapacific Tbk (DEFI.JK) Income Statement Analysis – Financial Results
- Nanoforce, Inc. (NNFC) Income Statement Analysis – Financial Results
WuXi XDC Cayman Inc (2268.HK)
About WuXi XDC Cayman Inc
WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. The company was founded in 2013 and is headquartered in Wuxi, China. WuXi XDC Cayman Inc. operates as a subsidiary of WuXi Biologics (Cayman) Inc.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 2.12B | 990.42M | 311.13M | 96.35M |
| Cost of Revenue | 1.56B | 729.34M | 197.64M | 88.27M |
| Gross Profit | 559.56M | 261.08M | 113.49M | 8.08M |
| Gross Profit Ratio | 26.35% | 26.36% | 36.48% | 8.39% |
| Research & Development | 76.87M | 33.84M | 13.82M | 4.08M |
| General & Administrative | 123.97M | 49.21M | 27.86M | 9.61M |
| Selling & Marketing | 15.22M | 8.77M | 2.03M | 478.00K |
| SG&A | 117.19M | 57.98M | 29.89M | 10.09M |
| Other Expenses | 0.00 | 6.15M | 8.17M | 1.77M |
| Operating Expenses | 194.06M | 76.04M | 42.80M | -25.48M |
| Cost & Expenses | 1.76B | 805.38M | 240.44M | 62.79M |
| Interest Income | 47.36M | 4.61M | 28.00K | 31.00K |
| Interest Expense | 742.00K | 2.92M | 493.00K | 0.00 |
| Depreciation & Amortization | 54.78M | 30.81M | 18.98M | 13.47M |
| EBITDA | 420.28M | 272.90M | 96.89M | 46.12M |
| EBITDA Ratio | 19.79% | 27.55% | 31.14% | 47.87% |
| Operating Income | 365.50M | 242.09M | 77.90M | 32.66M |
| Operating Income Ratio | 17.21% | 24.44% | 25.04% | 33.89% |
| Total Other Income/Expenses | -5.89M | 69.91M | -3.84M | 38.74M |
| Income Before Tax | 359.61M | 195.80M | 66.85M | 32.37M |
| Income Before Tax Ratio | 16.93% | 19.77% | 21.49% | 33.59% |
| Income Tax Expense | 76.07M | 40.07M | 11.92M | 6.07M |
| Net Income | 283.54M | 155.73M | 54.93M | 26.30M |
| Net Income Ratio | 13.35% | 15.72% | 17.65% | 27.29% |
| EPS | 0.26 | 0.13 | 0.05 | 0.02 |
| EPS Diluted | 0.26 | 0.13 | 0.05 | 0.02 |
| Weighted Avg Shares Out | 1.09B | 1.18B | 1.18B | 1.18B |
| Weighted Avg Shares Out (Dil) | 1.08B | 1.18B | 1.18B | 1.18B |
Source: https://incomestatements.info
Category: Stock Reports